About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Outcomes Using MARS for Patients With ALF | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT05594953

Outcomes Using MARS for Patients With ALF

Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free s...

Lead sponsor: Methodist Health System•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Crystee Cooper, DHEd

CONTACT

214-947-1280 clinicalresearch@mhd.com

Zaid Haddadin, MS

CONTACT

214-947-1280 clinicalresearch@mhd.com

Sponsors

Lead Sponsor

Methodist Health System

Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures. Patient's charts will be accessed on EPIC by the PI or delegated study personnel. The investigator's anticipate completion of this study by January 31, 2022.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•The patient was diagnosed with: Alcoholic hepatitis; AoCLF; OR Acute fulminant liver failure
•The patient underwent at least one round of dialysis using plasma exchange or MARSTM
•All patients who underwent MARS at MDMC will be included in the study population.

Related studies

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

NCT07329036 · Acute Liver Failure

Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure

NCT06831643 · Acute Liver Failure

Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis

NCT04088370 · Alcoholic Hepatitis

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

NCT07060547 · Alcoholic Hepatitis, Alcohol-related Liver Disease

Intestinal Microbiota Profiling in Severe Acute Alcoholic Hepatitis Patients

NCT06159244 · Severe Acute Alcoholic Hepatitis, Alcohol, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 27, 2024Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment30

Start dateApr 2021

Last updatedMar 27, 2024

Condition

Alcoholic Hepatitis Acute Liver Failure

Locations shown

Methodist Dallas Medical Center

Dallas, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 27, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions